Sequential treatment with monofluorophosphate and zoledronic acid in osteoporotic rats

References

• Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science 1983;222:330–2
   PubMed Web of Science ®Google Scholar
• Lau KH, Farley JR, Freeman TK, Baylink DJ. A proposed mechanism of the mitogenic action of fluoride on bone cells inhibition of the activity of an osteoblastic acid phosphatase. Metabolism 1989;38:858–68
   PubMed Web of Science ®Google Scholar
• Briançon D, Meunier PJ. Treatment of osteoporosis with fluoride, calcium and vitamin D. Orthop Clin North Am 1981;12:629–48
   PubMed Web of Science ®Google Scholar
• Sebert JL, Richard P, Mennecier I, Bisset JP, Loeb G. Monofluorophosphate increase lumbar bone density in osteopenic patients: A double-masked randomized study. Osteoporos Int 1995;5:108–14
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Spinetti A, Taponeco F, et al. Treatment of postmenopausal vertebral osteopenia with monofluorophospate: a long-term calcium-controlled study. Osteoporos Int 1995;5: 467–71
   PubMed Web of Science ®Google Scholar
• Ringe JD, Kipshoven C, Cöster A, Umbach R. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate. Osteoporos Int 1999;9:171–8
   PubMed Web of Science ®Google Scholar
• Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802–9
   PubMed Web of Science ®Google Scholar
• Reginster JY, Meurmans L, Zegels B, et al. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 1998;129:1–8
   PubMed Web of Science ®Google Scholar
• Reid IR, Cundy T, Grey AB, et al. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2007;92:2446–52
   PubMed Web of Science ®Google Scholar
• Ringe JD, Setnikar I. Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study. Rheumatol Int 2002;22:27–32
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Jorgensen NR, Schwarz P, Mosekilde L. Effects of treatment with fluoride on bone mineral density and fracture risk: a meta-analysis. Osteoporos Int 2008;19:257–68
   PubMed Web of Science ®Google Scholar
• Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004;75:451–61
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104: 1363–74
   PubMed Web of Science ®Google Scholar
• Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000;85:720–6
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003;289:2525–33
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349: 1207–15
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 2005;353:555–65
   PubMed Web of Science ®Google Scholar
• Reginster JY, Felsenberg D, Pavo I, et al. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int 2003; 14:741–9
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22
   PubMed Web of Science ®Google Scholar
• Pataki A, Müller K, Green JR, Ma YF, Li QN, Jee WS. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 1997;249:458–68
   PubMedGoogle Scholar
• De Candia F, Rigalli A, Di Loreto V. Anesthesia and analgesia. In Rigalli A, Di Loreto V, eds. Experimental Surgical Models in the Laboratory Rat, 1st edn. Boca Raton: CRC Press, 2009: 21–30
   Google Scholar
• Kalu DN. The ovariectomized rat model for postmenopausal bone loss. Bone Miner 1991;15:175–92
   PubMedGoogle Scholar
• Bagi CM, Ammann P, Rizzoli R, Miller SC. Effect of estrogen deficiency on cancellous and cortical bone structure and strength of the femoral neck in rats. Calcif Tissue Int 1997;61: 336–44
   PubMed Web of Science ®Google Scholar
• Canadian Council on Animal Care Guidelines. Guide to the care and use of experimental animal, 2nd edn., 1998
   Google Scholar
• Rigalli A, Pera LI, Di Loreto V, Brun LR. Determinación de la concentración de flúor en muestras biológicas, 1st edn. Argentina: Editorial Universidad Nacional de Rosario, 2007
   Google Scholar
• Farley JR, Chesnut CJ, Baylink DJ. Improved method for quantitative determination in serum alkaline phosphatase of skeletal origin. Clin Chem 1981;27:2002–7
   PubMed Web of Science ®Google Scholar
• Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595–609
   PubMed Web of Science ®Google Scholar
• Zeni SN, Gregorio S, Gomez AC, Somoza J, Mautalen C. Olpadronate prevents the bone loss induced by cyclosporine in the rat. Calcif Tissue Int 2002;70:48–53
   PubMed Web of Science ®Google Scholar
• Stürmer EK, Seidlová-Wuttke D, Sehmisch S, et al. Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene. J Bone Miner Res 2006;21:89–96
   PubMed Web of Science ®Google Scholar
• Hogan HA, Ruhmann SP, Sampson HW. The mechanical properties of cancellous bone in the proximal tibia of ovariectomized rats. J Bone Miner Res 2000;15:284–92
   PubMed Web of Science ®Google Scholar
• Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause. N Engl J Med 2003; 349:327–34
   PubMed Web of Science ®Google Scholar
• Beinlich A, Brun L, Rigalli A, Puche RC. Intestinal absorption of disodium monofluorophosphate in rat as affected by concurrent administration of calcium. Arzneimittelforschung 2003;53: 584–9
   PubMed Web of Science ®Google Scholar
• Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 1996;11:150–9
   PubMed Web of Science ®Google Scholar
• Pataki A, Müller K, Green JR, Ma YF, Li QN, Jee WS. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 1997; 249:458–68
   PubMedGoogle Scholar
• Glatt M, Pataki A, Evans GP, Hornby SB, Green JR. Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int 2004; 15:707–15
   PubMed Web of Science ®Google Scholar